HOME >> BIOLOGY >> NEWS
Rimonbant shows promise in addressing multiple risk factors

Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost almost 20 lbs (8.6 kg) when treated for a year with rimonabant 20mg. Weight loss was accompanied by a decrease in waist size of 3.4 inches (9.1 cm) demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease. Dramatic improvements were also seen in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also observed. In another important finding, the number of patients diagnosed at baseline with metabolic syndrome,1 who were treated with rimonabant 20mg, was reduced by half. The drug was also found to be safe and well-tolerated.

Rimonabant works by inhibiting the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

"While the weight loss was clinically relevant, what is truly remarkable in the RIO-Lipids study is the significant effect rimonabant had on improving associated cardiovascular risk factors," said Jean-Pierre Despr's, principal investigator for RIO-Lipids and Professor in the Department of Food Sciences and Nutrition and Medicine at Laval University, and Director of Research at the Quebec Heart Institute located at the Laval Hospital Center in Quebec City, Canada. "Rimonabant appears to have a direct effect on fat cells which may be contributing to the beneficial effects of this drug on abdominal obesity and associated risk factors. Couple this with the markedly
'"/>

Contact: Glenn Lehrman
glenn.lehrman@ketchum.com
917-533-5998
Ketchum
9-Mar-2004


Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
Cached News: